1413TiP LIBRETTO-431: Selpercatinib in treatment (Tx)-naïve patients with RET fusion-positive (RET+) non-small cell lung cancer (NSCLC)

MLA

Yasir Elamin, et al. “1413TiP LIBRETTO-431: Selpercatinib in Treatment (Tx)-Naïve Patients with RET Fusion-Positive (RET+) Non-Small Cell Lung Cancer (NSCLC).” Annals of Oncology, vol. 31, Sept. 2020, p. S893. EBSCOhost, https://doi.org/10.1016/j.annonc.2020.08.1727.

APA

Yasir Elamin, Geoffrey R. Oxnard, Victoria Soldatenkova, Juergen Wolf, Andreas Sashegyi, C. Zhou, Herbert H. Loong, A. Drilon, Fernando C. Santini, K. Park, Boris Lin, Ben Solomon, Koichi Goto, & A. Bence Lin. (2020). 1413TiP LIBRETTO-431: Selpercatinib in treatment (Tx)-naïve patients with RET fusion-positive (RET+) non-small cell lung cancer (NSCLC). Annals of Oncology, 31, S893. https://doi.org/10.1016/j.annonc.2020.08.1727

Chicago

Yasir Elamin, Geoffrey R. Oxnard, Victoria Soldatenkova, Juergen Wolf, Andreas Sashegyi, C. Zhou, Herbert H. Loong, et al. 2020. “1413TiP LIBRETTO-431: Selpercatinib in Treatment (Tx)-Naïve Patients with RET Fusion-Positive (RET+) Non-Small Cell Lung Cancer (NSCLC).” Annals of Oncology 31 (September): S893. doi:10.1016/j.annonc.2020.08.1727.